Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INNOVATIVE MEDTECH, INC. (FRHV)
|
Add to portfolio |
|
|
|
| Price: |
$0.72
| | Metrics |
| OS: |
21.2
|
M
| |
|
|
| Market cap: |
$15.1
|
M
| |
|
|
|
Net debt:
|
$1.6
|
M
| |
|
|
|
EV:
|
$16.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 10/13/2023 |
10-K
| Annual Report for the period ended June 30, 2023 |
| 09/28/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/13/2022 |
10-K
| Annual Report for the period ended June 30, 2022 |
| 09/27/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 06/28/2022 |
3
| Griff Merle (CEO) has filed a Form 3 on INNOVATIVE MEDTECH, INC. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-22 | Jun-30-21 | Jun-30-20 | Oct-31-14 | Oct-31-13 | Oct-31-12 | Oct-31-11 | Oct-31-10 |
| Revenues | 1.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.6 |
| Revenue growth | 271.7% | | | | -100.0% | -54.1% | -108.4% | 637.2% |
| Cost of goods sold | 0.9 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
| Gross profit | 0.4 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.1 |
| Gross margin | 29.0% | 43.3% | | | | 100.0% | 100.0% | 13.5% |
| Sales and marketing | | | | 0.1 | 0.1 | 0.6 | 0.1 | 0.3 |
| General and administrative | 1.0 | 0.6 | 0.3 | 0.2 | 0.2 | 0.8 | 0.9 | 0.5 |
| EBITA | -18.2 | -1.5 | -0.4 | -0.3 | -0.3 | -1.4 | -1.0 | -1.9 |
| EBITA margin | -1405.0% | -433.3% | | | | 5466.9% | 1750.8% | -297.0% |
| Amortization of intangibles | 0.0 | | | | | | | |
| EBIT | -18.3 | -1.5 | -0.4 | -0.3 | -0.3 | -1.4 | -1.0 | -1.9 |
| EBIT margin | -1407.1% | -433.3% | | | | 5466.9% | 1750.8% | -297.0% |
| Pre-tax income | 0.0 | 0.0 | 0.0 | -0.4 | -0.6 | -1.5 | -1.1 | -2.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -18.1 | -3.3 | -0.5 | -0.4 | -0.6 | -1.5 | -1.1 | -2.0 |
| Net margin | -1391.7% | -935.1% | | | | 5829.4% | 2004.7% | -312.5% |
| |
| Diluted EPS | ($1.09) | ($1.54) | ($1.68) | $0.00 | $0.00 | $0.00 | $0.00 | ($0.01) |
| Shares outstanding (diluted) | 16.6 | 2.1 | 0.3 | 1,635.6 | 1,635.6 | 944.7 | 226.7 | 201.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|